Trial Profile
Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Colon cancer; Colorectal cancer
- Focus Diagnostic use
- 05 Oct 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 06 Sep 2019 Status changed from not yet recruiting to recruiting.
- 31 May 2019 Planned initiation date changed from 1 Apr 2019 to 1 Aug 2019.